Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study.
Marcellin P, Arama V, Leblebicioglu H, Zarski JP, Zeuzem S, Mauss S, Sieklucki J, Acalovschi M, Usluer G, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Simon K; AI463-121 European Longitudinal Chronic Hepatitis B Study Group. Marcellin P, et al. Among authors: zarski jp. Antivir Ther. 2014;19(3):235-43. doi: 10.3851/IMP2573. Epub 2013 Apr 10. Antivir Ther. 2014. PMID: 23574686
Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies.
Arama V, Leblebicioglu H, Simon K, Zarski JP, Niederau C, Habersetzer F, Vermehren J, Bludzin W, Jinga M, Ulusoy S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zeuzem S; AI463-121 European Longitudinal Chronic Hepatitis B Study Group. Arama V, et al. Among authors: zarski jp. Antivir Ther. 2014;19(3):245-57. doi: 10.3851/IMP2719. Epub 2013 Dec 17. Antivir Ther. 2014. PMID: 24343051
Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries.
Leblebicioglu H, Arama V, Causse X, Marcellin P, Ozaras R, Postawa-Klozinska B, Simon K, Suceveanu AI, Wiese M, Zeuzem S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zarski JP; AI463-121 European Longitudinal Chronic Hepatitis B Study Group. Leblebicioglu H, et al. Among authors: zarski jp. J Viral Hepat. 2014;21(9):662-70. doi: 10.1111/jvh.12202. Epub 2013 Dec 15. J Viral Hepat. 2014. PMID: 24329883
High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients.
Marcellin P, Cadranel JF, Fontanges T, Poynard T, Pol S, Trepo C, Blin P, Bregman B, Schmidely N, Roudot-Thoraval F, Zarski JP. Marcellin P, et al. Among authors: zarski jp. Eur J Gastroenterol Hepatol. 2010 Nov;22(11):1290-6. doi: 10.1097/meg.0b013e32832fba4f. Eur J Gastroenterol Hepatol. 2010. PMID: 20964259
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France.
Marcellin P, Zoulim F, Hézode C, Causse X, Roche B, Truchi R, Pauwels A, Ouzan D, Dumortier J, Pageaux GP, Bourlière M, Riachi G, Zarski JP, Cadranel JF, Tilliet V, Stern C, Pétour P, Libert O, Consoli SM, Larrey D. Marcellin P, et al. Among authors: zarski jp. Dig Dis Sci. 2016 Oct;61(10):3072-3083. doi: 10.1007/s10620-015-4027-8. Epub 2016 Jan 28. Dig Dis Sci. 2016. PMID: 26821154 Free PMC article.
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.
Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B, Gane E, Schuchmann M, Lohse AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Nehmiz G, Kukolj G, Böcher WO, Mensa FJ. Zeuzem S, et al. Among authors: zarski jp. Antivir Ther. 2013;18(8):1015-9. doi: 10.3851/IMP2567. Epub 2013 Apr 4. Antivir Ther. 2013. PMID: 23558093 Clinical Trial.
Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.
Snoeck E, Hadziyannis SJ, Puoti C, Swain MG, Berg T, Marcellin P, Zarski JP, Jorga K, Zeuzem S. Snoeck E, et al. Among authors: zarski jp. Liver Int. 2008 Jan;28(1):61-71. doi: 10.1111/j.1478-3231.2007.01603.x. Epub 2007 Oct 25. Liver Int. 2008. PMID: 17971091
280 results